Ligand Pharmaceuticals, Inc. (LGND)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Ligand Pharmaceuticals, Inc. (LGND)
Go deeper and ask any question about LGND
Company Performance
Current Price
as of Sep 13, 2024$104.77
P/E Ratio
45.32
Market Cap
$1.91B
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Metrics
Overview
- HQJupiter, FL
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerLGND
- Price$104.77+2.62%
Trading Information
- Market Cap$1.91B
- Float97.65%
- Average Daily Volume (1m)95,671
- Average Daily Volume (3m)122,977
- EPS$2.43
Company
- Revenue$133.48M
- Rev Growth (1yr)57.52%
- Net Income-$51.91M
- Gross Margin73.12%
- EBITDA Margin40.33%
- EBITDA$16.75M
- EV$1.30B
- EV/Revenue9.74
- P/E45.32
- P/S14.15
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia